ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
- PMID: 35486267
- PMCID: PMC9492574
- DOI: 10.1245/s10434-022-11842-4
ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
Conflict of interest statement
The authors have no conflict of interest to disclose.
Comment on
-
Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Versus Metachronous Onset of Peritoneal Metastases of Colorectal Carcinoma.Ann Surg Oncol. 2022 Oct;29(11):6566-6576. doi: 10.1245/s10434-022-11805-9. Epub 2022 May 5. Ann Surg Oncol. 2022. PMID: 35513588 Free PMC article.
References
-
- Hentzen JEKR, Kuipers H, van der Plas WY, Been LB, Hoogwater FJH, et al. Impact of synchronous versus metachronous onset of colorectal peritoneal metastases on survival outcomes after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a multicenter, retrospective, observational study. Ann Surg Oncol. 2019;26:2210–2221. doi: 10.1245/s10434-019-07294-y. - DOI - PMC - PubMed
-
- Dietz MV, van Kooten JP, Said I, Brandt-Kerkhof ARM, Verhoef C, Bremers AJA, de Wilt JHW, de Reuver PR, Madsen EVE. Survival outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with synchronous versus metachronous onset of peritoneal metastases of colorectal carcinoma. Ann Surg Oncol. 2022. 10.1245/s10434-022-11805-9. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
